Subscribe
Conference Correspondent

Subgroup Analysis from REVEL: Safety by Histology and Efficacy in Nonsquamous NSCLC

Conference Correspondent - ASCO 2015 - Lung Cancer

REVEL, a global, randomized phase 3 study inclusive of nonsquamous (NSQ) and squamous (SQ) NSCLC, led to FDA approval of second-line ramucirumab plus docetaxel (RAM+DOC) for patients with metastatic NSCLC based on improved overall survival (OS).a Neutropenia, febrile neutropenia, gastrointestinal, and pulmonary hemorrhage events were similar across NSQ and SQ histologies. In the presentation by Paz-Ares and colleagues,b a subanalysis of REVEL by histologic subgroups was shown in which 1,253 patients with SQ or NSQ NSCLC received DOC (75 mg/m2) plus RAM (10 mg/kg; N = 628) or placebo (N = 625) after disease progression on platinum-based therapy. Endpoints evaluated in specified histologic subgroups were OS, progression-free survival (PFS), response rates, safety, and quality of life (QoL) analyzed by time to deterioration (TtD) on the Lung Cancer Symptom scale (LCSS). Of the 73% (N = 912) of NSQ tumors, the majority were adenocarcinoma (79%; N = 725).

Efficacy outcomes for patients with adenocarcinoma were similar to the NSQ population (see Table). Incidences of patients with ≥ 1 treatment-emergent adverse event (TEAE), ≥ 1 serious adverse event, TEAEs grade ≥ 3, and TEAEs leading to dose adjustment or discontinuation were similar between treatment arms and across NSQ and SQ histologies. The TtD for total LCSS score was similar between treatment arms in NSQ and SQ subgroups. This subanalysis of REVEL demonstrated an acceptable benefit/risk profile for RAM+DOC, with favorable efficacy and manageable safety outcomes seen across SQ, adenocarcinoma, and NSQ histologic subtypes of NSCLC, with no impairment of QoL.


Click table to enlarge

  1. Garon EB, et al. Lancet. 2014;384:665-673.
  2. Paz-Ares L, et al. ASCO 2015. Abstract 8055.

 

Related Items
Afatinib vs Erlotinib as Second-line Therapy of Patients with Advanced Squamous Cell Carcinoma (SCC) of the Lung: Analysis from the LUX-Lung 8 Trial
Conference Correspondent published on May 31, 2015 in ASCO 2015 - Lung Cancer
Final Follow-up Results from RADIANT: Adjuvant Erlotinib Vs Placebo Following Complete Tumor Resection in Patients with Stage IB–IIIA EGFR-positive NSCLC
Conference Correspondent published on May 28, 2015 in ASCO 2015 - Lung Cancer
GASTO 1001: a Phase 2 Trial of Neoadjuvant Bevacizumab plus Pemetrexed and Carboplatin in Patients with Unresectable Stage III Lung Adenocarcinoma
Conference Correspondent published on May 28, 2015 in ASCO 2015 - Lung Cancer
ASCEND-3: a Phase 2 Study of Ceritinib in ALK Inhibitor-Naïve Adult Patients with ALK+ NSCLC
Conference Correspondent published on May 28, 2015 in ASCO 2015 - Lung Cancer
Efficacy and Safety of BCD-021, a Bevacizumab Biosimilar Candidate, Compared to Avastin® in Patients with Advanced Nonsquamous NSCLC
Conference Correspondent published on May 28, 2015 in ASCO 2015 - Lung Cancer
PD-L1, PD-1, and CTLA-4 as Prognostic Biomarkers in Resected NSCLC
Conference Correspondent published on May 28, 2015 in ASCO 2015 - Lung Cancer
First-line Monotherapy with Nivolumab in Advanced NSCLC: Safety, Efficacy, and Correlation of Outcomes with PD-L1 Expression
Conference Correspondent published on May 28, 2015 in ASCO 2015 - Lung Cancer
Results from the GENIUS Trial: Maintenance Therapy with Gefitinib/Pemetrexed vs Pemetrexed for Metastatic Lung Adenocarcinoma with No Sensitizing EGFR Mutation
Conference Correspondent published on May 28, 2015 in ASCO 2015 - Lung Cancer
Docetaxel plus Ramucirumab vs Docetaxel plus Placebo as Second-line Treatment for Advanced NSCLC: a Phase 2 Multicenter Trial in Japan
Conference Correspondent published on May 28, 2015 in ASCO 2015 - Lung Cancer
Results from the REVEL Trial: Exposure-Response Relationship for Ramucirumab plus Docetaxel vs Docetaxel as Second-line Treatment of Metastatic NSCLC
Conference Correspondent published on May 28, 2015 in ASCO 2015 - Lung Cancer
Last modified: December 16, 2015
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology